307 related articles for article (PubMed ID: 35495127)
41. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
42. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Barry ER; Corry GN; Rasmussen TP
Expert Opin Ther Targets; 2010 Apr; 14(4):405-18. PubMed ID: 20230194
[TBL] [Abstract][Full Text] [Related]
43. Methyltransferase Dot1l preferentially promotes innate IL-6 and IFN-β production by mediating H3K79me2/3 methylation in macrophages.
Chen X; Liu X; Zhang Y; Huai W; Zhou Q; Xu S; Chen X; Li N; Cao X
Cell Mol Immunol; 2020 Jan; 17(1):76-84. PubMed ID: 30275539
[TBL] [Abstract][Full Text] [Related]
44. DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation.
Cao K; Ugarenko M; Ozark PA; Wang J; Marshall SA; Rendleman EJ; Liang K; Wang L; Zou L; Smith ER; Yue F; Shilatifard A
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27365-27373. PubMed ID: 33077595
[TBL] [Abstract][Full Text] [Related]
45. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
Bon C; Si Y; Pernak M; Barbachowska M; Levi-Acobas E; Cadet Daniel V; Jallet C; Ruzic D; Djokovic N; Djikić T; Nikolic K; Halby L; Arimondo PB
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500733
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer.
Byun WS; Lee GH; Park HG; Lee SK
Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33379275
[TBL] [Abstract][Full Text] [Related]
48. Histone methyltransferase Dot1L inhibits pancreatic cancer cell apoptosis by promoting NUPR1 expression.
Shan L; Hao C; Jun Z; Qinghe C
J Int Med Res; 2022 Mar; 50(3):3000605221088431. PubMed ID: 35350907
[TBL] [Abstract][Full Text] [Related]
49. Connecting the DOTs on Cell Identity.
Wille CK; Sridharan R
Front Cell Dev Biol; 2022; 10():906713. PubMed ID: 35733849
[TBL] [Abstract][Full Text] [Related]
50. Human histone H3K79 methyltransferase DOT1L protein [corrected] binds actively transcribing RNA polymerase II to regulate gene expression.
Kim SK; Jung I; Lee H; Kang K; Kim M; Jeong K; Kwon CS; Han YM; Kim YS; Kim D; Lee D
J Biol Chem; 2012 Nov; 287(47):39698-709. PubMed ID: 23012353
[TBL] [Abstract][Full Text] [Related]
51. Combinatorial targeting of menin and the histone methyltransferase DOT1L as a novel therapeutic strategy for treatment of chemotherapy-resistant ovarian cancer.
Alexandrova E; Lamberti J; Memoli D; Quercia C; Melone V; Rizzo F; Tarallo R; Giurato G; Nassa G; Weisz A
Cancer Cell Int; 2022 Nov; 22(1):336. PubMed ID: 36333801
[TBL] [Abstract][Full Text] [Related]
52. miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L.
Lv L; Li Q; Chen S; Zhang X; Tao X; Tang X; Wang S; Che G; Yu Y; He L
Exp Cell Res; 2019 Dec; 385(1):111597. PubMed ID: 31525340
[TBL] [Abstract][Full Text] [Related]
53. DOT1L Mediated Gene Repression in Extensively Self-Renewing Erythroblasts.
Borosha S; Ratri A; Ghosh S; Malcom CA; Chakravarthi VP; Vivian JL; Fields TA; Rumi MAK; Fields PE
Front Genet; 2022; 13():828086. PubMed ID: 35401699
[TBL] [Abstract][Full Text] [Related]
54. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor.
Chen J; Park HJ
ACS Chem Biol; 2019 May; 14(5):873-881. PubMed ID: 30951287
[TBL] [Abstract][Full Text] [Related]
55. Differential Methylation of H3K79 Reveals DOT1L Target Genes and Function in the Cerebellum In Vivo.
Bovio PP; Franz H; Heidrich S; Rauleac T; Kilpert F; Manke T; Vogel T
Mol Neurobiol; 2019 Jun; 56(6):4273-4287. PubMed ID: 30302725
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
[TBL] [Abstract][Full Text] [Related]
57. The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
Salvati A; Gigantino V; Nassa G; Giurato G; Alexandrova E; Rizzo F; Tarallo R; Weisz A
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31689915
[TBL] [Abstract][Full Text] [Related]
58. The emerging role of DOT1L in cell proliferation and differentiation: Friend or foe.
Wu D; Zhang J; Jun Y; Liu L; Huang C; Wang W; Yang C; Xiang Z; Wu J; Huang Y; Meng D; Yang Z; Zhou X; Cheng C; Yang J
Histol Histopathol; 2024 Apr; 39(4):425-435. PubMed ID: 37706592
[TBL] [Abstract][Full Text] [Related]
59. The role of DOT1L in the proliferation and prognosis of gastric cancer.
Song Z; Wei Z; Wang Q; Zhang X; Tao X; Wu N; Liu X; Qian J
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31939604
[TBL] [Abstract][Full Text] [Related]
60. The many faces of histone H3K79 methylation.
Farooq Z; Banday S; Pandita TK; Altaf M
Mutat Res Rev Mutat Res; 2016; 768():46-52. PubMed ID: 27234562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
